Flexion Therapeutics

Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late-stage development for moderate to severe osteoarthritis pain.

Zilretta™ has received Fast Track Designation from the FDA. This designation is given to a drug in clinical development that is intended to treat a serious condition and addresses unmet medical need.

Company Growth (employees)
Type
Public
HQ
Burlington, US
Founded
2007
Size (employees)
95 (est)+98%
Flexion Therapeutics was founded in 2007 and is headquartered in Burlington, US

Key People at Flexion Therapeutics

Mike Clayman

Mike Clayman

Chief Executive Officer & Co-Founder
Neil Bodick

Neil Bodick

Chief Medical Officer & Co-Founder

Flexion Therapeutics Office Locations

Flexion Therapeutics has an office in Burlington
Burlington, US (HQ)
301 10 Burlington Mall Road

Flexion Therapeutics Data and Metrics

Flexion Therapeutics Financial Metrics

Flexion Therapeutics's revenue was reported to be $0 in Q3, 2016
USD

Net income (Q1, 2017)

(23.9 m)

EBIT (Q1, 2017)

(23.8 m)

Market capitalization (25-Jul-2017)

766.3 m

Cash (31-Mar-2017)

42.9 m
Flexion Therapeutics's current market capitalization is $766.3 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

17.9 m32.7 m41.3 m

General and administrative expense

9.1 m13.4 m28.5 m

Operating expense total

27 m46.1 m69.8 m

EBIT

(27 m)(46.1 m)(69.8 m)

Interest expense

(401.4 k)(571 k)(1.7 m)

Interest income

478.7 k1.2 m1.5 m

Net Income

(27.3 m)(46.3 m)(71.9 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

6.3 m9.6 m7.8 m12 m8.9 m9 m10.8 m

General and administrative expense

2.8 m2.9 m3.2 m4.7 m5.2 m8.4 m13 m

Operating expense total

9 m12.5 m11 m16.7 m14.1 m17.4 m23.8 m

EBIT

(9 m)(12.5 m)(11 m)(16.7 m)(14.1 m)(17.4 m)(23.8 m)

Interest expense

(203.5 k)(106 k)(202.4 k)(276 k)(202 k)(561 k)(632 k)

Interest income

168.4 k440 k273.7 k336 k295 k421 k557 k

Net Income

(9.2 m)(21.6 m)(11.1 m)(16.8 m)(14.2 m)(17.8 m)(23.9 m)
USDFY, 2014FY, 2015FY, 2016

Cash

103.1 m62.9 m30.9 m

Accounts Receivable

95.3 k55.8 m

Inventories

502.3 k760.9 k3.8 m

Current Assets

152.1 m112.1 m209.4 m

PP&E

1.1 m7.4 m11.7 m

Total Assets

153.4 m127.1 m226.3 m

Accounts Payable

1.6 m3.7 m2.2 m

Total Debt

3.6 m17 m30.5 m

Current Liabilities

6.8 m8.1 m17.5 m

Total Liabilities

39.2 m

Additional Paid-in Capital

238.4 m243.9 m398.8 m

Retained Earnings

(93.5 m)(139.8 m)(211.7 m)

Total Equity

144.9 m104 m187 m

Debt to Equity Ratio

0 x0.2 x0.2 x

Debt to Assets Ratio

0 x0.1 x0.1 x

Financial Leverage

1.1 x1.2 x1.2 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

28.3 m73.5 m58.9 m119 m66.8 m42.9 m

Accounts Receivable

199.6 k46.4 k56 k101 k95 k

Current Assets

128.8 m133 m99.6 m164.5 m161.1 m190.1 m

PP&E

2.9 m4.2 m9.1 m11.3 m11.2 m11.8 m

Total Assets

131.8 m137.2 m112.1 m176 m174.4 m204.3 m

Accounts Payable

1.3 m1.9 m3.1 m3.5 m2 m2.2 m

Current Liabilities

6.1 m6.6 m8.3 m8.2 m12.4 m18 m

Additional Paid-in Capital

240.7 m241.9 m245.5 m324.8 m326.6 m401.7 m

Retained Earnings

(115.1 m)(126.2 m)(156.6 m)(170.8 m)(188.6 m)(235.6 m)

Total Equity

125.7 m115.7 m88.9 m154 m138 m166.1 m

Financial Leverage

1 x1.2 x1.3 x1.1 x1.3 x1.2 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(27.3 m)(46.3 m)(71.9 m)

Depreciation and Amortization

120.3 k238.2 k1.2 m

Accounts Receivable

95.3 k

Inventories

(9.1 m)46.9 m(34 m)

Accounts Payable

518 k1.6 m(992.7 k)

Cash From Operating Activities

(23.1 m)(38.9 m)(62.5 m)

Purchases of PP&E

(802.5 k)(5.2 m)(8.4 m)

Cash From Investing Activities

(49.5 m)(13.2 m)(132.8 m)

Cash From Financing Activities

159.5 m12 m163.2 m

Interest Paid

364.9 k572.3 k1.3 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9.2 m)(21.6 m)(11.1 m)(16.8 m)(14.2 m)(17.8 m)(23.9 m)

Depreciation and Amortization

39.7 k82.4 k

Accounts Receivable

(403.2 k)(199.6 k)46.4 k56 k101 k95 k

Accounts Payable

592.8 k(196.2 k)1.9 m3.1 m3.5 m2 m2.2 m

Cash From Operating Activities

(10 m)(19 m)

Purchases of PP&E

(533.1 k)(1.4 m)

Cash From Investing Activities

(62.5 m)(52.3 m)

Cash From Financing Activities

(3.7 m)(3.4 m)

Interest Paid

292 k292 k
Y, 2017

Financial Leverage

1.2 x

Flexion Therapeutics Market Value History

Flexion Therapeutics Online and Social Media Presence

Flexion Therapeutics Company Life and Culture

You may also be interested in